Into the clinic: Talimogene laherparepvec (T-VEC), a first-in-class intratumoral oncolytic viral therapy.
Into the clinic: Talimogene laherparepvec (T-VEC), a first-in-class intratumoral oncolytic viral therapy.
复制标题
DOI:
10.1186/s40425-016-0158-5
复制
发表时间:
2016
影响因子:
10.9
通讯作者:
Kaufman HL
中科院分区:
文献类型:
--
作者:
Rehman H;Silk AW;Kane MP;Kaufman HL
With the recent regulatory approval of Talimogene laherparepvec (T-VEC) for the treatment of advanced of melanoma in the United States, Europe and Australia, oncolytic virus immunotherapy has earned its place in the clinic. However, the adoption of T-VEC by the U.S. oncology community has been slow, and so far has been largely limited to specialized cancer centers. Limiting factors include the intratumoral route of administration, which is unfamiliar to medical oncologists, biosafety concerns related to the use of a live virus in the clinic, and the explosion of other therapeutic strategies now available for the treatment of advanced melanoma. Herein, we review the development of T-VEC, and suggest how it fits into the in the current clinical treatment paradigm, and provide pearls for drug preparation, administration, and monitoring of response to therapy.
登录
查看更多内容
DOI:
10.1056/nejmoa1003466
发表时间:
2010-08-19
期刊:
The New England journal of medicine
影响因子:
--
作者:
Hodi FS;O'Day SJ;McDermott DF;Weber RW;Sosman JA;Haanen JB;Gonzalez R;Robert C;Schadendorf D;Hassel JC;Akerley W;van den Eertwegh AJ;Lutzky J;Lorigan P;Vaubel JM;Linette GP;Hogg D;Ottensmeier CH;Lebbé C;Peschel C;Quirt I;Clark JI;Wolchok JD;Weber JS;Tian J;Yellin MJ;Nichol GM;Hoos A;Urba WJ
通讯作者:
Urba WJ
影响因子:
158.5
作者:
Robert, Caroline;Schachter, Jacob;Ribas, Antoni
通讯作者:
Ribas, Antoni
影响因子:
45.3
作者:
Senzer, Neil N.;Kaufman, Howard L.;Nemunaitis, John J.
通讯作者:
Nemunaitis, John J.
影响因子:
10.9
作者:
Kaufman HL;Amatruda T;Reid T;Gonzalez R;Glaspy J;Whitman E;Harrington K;Nemunaitis J;Zloza A;Wolf M;Senzer NN
通讯作者:
Senzer NN
影响因子:
11.5
作者:
Hu, Jennifer C. C.;Coffin, Robert S.;Coombes, R. Charles
通讯作者:
Coombes, R. Charles